Home / Centerstage / 2017 / august / Week 3 /
Gilead Sciences agrees to acquire Kite Pharma for approximately $11 billion, aiming to expand its presence in the emerging field of CAR-T therapy for cancer treatment. Kite Pharma's therapy, awaiting regulatory approval, shows promising potential in improving outcomes for patients with advanced cancer. This move reflects the growing importance of CAR-T therapy and Gilead's commitment to advancing innovative cancer treatments.
Sunday, 27 August, 2017